BBIO Q4 2025 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena

BBIOBridgeBio Pharma, Inc.

$14B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$154M+2521.2% YoY

Gross Profit

$139M90.0% margin

Operating Income

-$185M-120.1% margin

Net Income

-$197M-127.9% margin

EPS (Diluted)

$-1.00

QoQ Revenue Growth

+27.7%

Cash Flow

Operating Cash Flow

-$56M

Free Cash Flow

-$61M

Stock-Based Comp.

$35M

Balance Sheet

Total Assets

$936M

Total Liabilities

$3.0B

Stockholders' Equity

-$2.1B

Cash & Equivalents

$570M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$154M	$6M	+2521.2%
Gross Profit	$139M	$4M	+3553.6%
Operating Income	-$185M	-$226M	+18.0%
Net Income	-$197M	-$265M	+25.6%

Revenue Segments

Product

$254M67%

License and Service

$120M31%

Royalty

$7M2%